Navigation Links
MiMedx Group to Present at the 6th Annual OneMedForum
Date:12/11/2012

KENNESAW, Georgia, Dec. 11, 2012 /PRNewswire/ -- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that they will present at the 6th Annual OneMedForum in San Francisco.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, January 8th, at 10:00 a.m. Pacific Time at the Sir Francis Drake Hotel.  In addition, the executive management team will be attending the JP Morgan 30th Annual Healthcare Conference. A webcast of the OneMed presentation will be available on the Company's website, www.mimedx.com

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 100,000 implants to date to distributors and OEMs for application in the Wound care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.


'/>"/>
SOURCE MiMedx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
2. Separation Design Group Launches Crowd-Funding Campaign for Worlds Smallest Oxygen Machine
3. SafeCode Drug Technologies Corporation Identifies the Technology Group to Commence and Develop the Worlds First Prototype for its Next Generation Application for Drug Safety Administration
4. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
5. Premier Healthcare Alliance Awards 3-Year Group Purchasing Contract for Diaper and Adult Brief Waste Receptacles to Sinclair Worldwide
6. MedicalMine Inc.s ChARM EHR Receives ONC-ATCB Certification By Drummond Group
7. Systagenix begins pilot with ToolsGroup to optimise inventory levels
8. Connecticut Radiology Group Leverages MedInformatix RIS to Achieve Stage 1 Meaningful Use Objectives
9. New Total Joint Replacement Registry From Remedy Informatics Aims to Enable Orthopedic Outcomes Research and Improve Quality for Hospitals and Orthopedic Surgery Groups
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
11. Patient and Disability Groups Support Bill to Begin Market Pricing System for Home Medical Equipment in Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... RGN-137, GtreeBNT Co., Ltd., received a positive response ... clinical trial design for RGN-137 to treat epidermolysis ... gel that incorporates Thymosin beta 4 ("Tß4") as ...
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 2017 , ... Miro is the ultimate smart media center that offers a ... TV shows and much more apps for user exploration. Its innovative acoustic design with ... 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi connection ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... 2017 , ... IndustryArchive.Org . is announcing a new way for B2B ... now only pay for B.A.N.T. quality sales leads based on the Sellers decision to ... new reality that B2B buyers are controlling the sales process via the Internet and ...
Breaking Medicine News(10 mins):